The biggest change for pimples and acne in October 2026 is easier access to a proven prescription-strength treatment without a prescription. Dermatology care is also shifting toward simpler isotretinoin monitoring, continued use of benzoyl peroxide, and testing of a new oral drug for moderate-to-severe acne. Acne means clogged pores, blackheads, pimples, and inflamed lesions on the face, chest, or back. Teens and adults with mild breakouts have a new over-the-counter combination option, while people with painful, widespread, or scarring lesions still benefit most from direct clinical care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Globenewswire — Use this primary source to verify the official guidance.
- Read the official guidance from Globenewswire — Use this primary source to verify the official guidance.
Table of Contents
- Can you buy Epiduo without a prescription now?
- What is next for moderate-to-severe acne?
- Should you still use benzoyl peroxide?
- What do dermatologists still recommend?
Can you buy Epiduo without a prescription now?
Galderma said in its OTC switch announcement that FDA approved Differin Epiduo Gel on May 22, 2026 for over-the-counter sale. The product combines adapalene 0.1% with benzoyl peroxide 2.5%. It is cleared for acne in ages 12 and older, with availability expected in summer 2026.
The switch expands access without a doctor visit for qualifying buyers. Adapalene helps prevent clogged pores, while benzoyl peroxide targets acne bacteria and inflammation. The fixed combination suits users who need both actions and can follow label directions consistently.
- Age 12 or older with acne on the face, chest, or back
- Able to follow once-daily use, sun protection, and irritation warnings
- Ask a pharmacist or clinician first for pregnancy, severe nodular acne, or eczema-prone skin
What is next for moderate-to-severe acne?
Sagimet Biosciences said in its trial clearance update that FDA issued a Study May Proceed letter on Aug. 13, 2026 for oral denifanstat. Denifanstat blocks fatty-acid synthase, an enzyme linked to sebum production. The planned Phase 3 trial targets adolescents and adults with moderate-to-severe acne and was planned to start in the second half of 2026.
Two other access changes matter for severe disease. Almirall reported China approval on Jan. 29, 2026 for Seysara, or sarecycline, for inflammatory lesions of non-nodular moderate-to-severe acne in patients 9 and older. FDA also approved iPLEDGE monitoring changes for isotretinoin on Feb. 9, 2026, including at-home pregnancy tests in some cases and no monthly qualification for patients who cannot become pregnant, with rollout expected in late 2026.
Should you still use benzoyl peroxide?
FDA testing described in a benzene testing report examined 95 benzoyl peroxide acne products. More than 90% had undetectable or extremely low benzene levels. FDA concluded risk is very low under normal use.
One exception led to action. Zapzyt gel was voluntarily recalled after elevated benzene linked to heat and product breakdown. Readers can reduce risk by buying normal quantities, storing products at room temperature, discarding old or swollen tubes, and checking recall notices before use.
- Use a thin layer as directed, not spot-thick coats
- Stop and seek care for severe burning, swelling, blistering, or hives
- Do not stockpile tubes in hot cars, near heaters, or for years past expiry
What do dermatologists still recommend?
The American Academy of Dermatology guidelines, summarized in an AAD guideline update, were published in the Journal of the American Academy of Dermatology in 2024 and still cited in 2026. They strongly recommend benzoyl peroxide, topical retinoids, topical antibiotics, fixed combinations, oral doxycycline, and oral isotretinoin for severe disease. They conditionally support clascoterone, azelaic acid, salicylic acid, and hormonal options for selected patients.
For marks left after breakouts, SkinHealth Systems reported FDA clearance on July 7, 2026 for SkinStylus SteriLock microneedling for eye-area wrinkles in adults 22 and older across Fitzpatrick types I-VI. That adds to its existing clearance for facial acne scars in types I-III and abdominal scars. The device treats scars and wrinkles, not active pimples, so ask whether your scar type and skin tone match the cleared use before booking treatment.
You Might Also Like
- Pretreatment Pregnancy Testing Under iPLEDGE in 2026: What the FDA Update Means for Parents of Teens With Severe Acne
- Planned Home Pregnancy Testing Under the 2026 iPLEDGE Changes: What the FDA Update Means for Parents of Teens With Severe Acne
- How to Verify Inflammation and Acne Claims in 2026: FDA and dermatology sources, Evidence, and Red Flags